Spectrum Pharma (SPPI) Tops Q3 EPS by 19c
Get Alerts SPPI Hot Sheet
EPS Growth %: +100.0%
Financial Fact:
Selling, general and administrative: 19.47M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Spectrum Pharma (NASDAQ: SPPI) reported Q3 EPS of ($0.22), $0.19 better than the analyst estimate of ($0.41).
“Spectrum has an expanding pipeline, significant near-term milestones, solid capitalization and a highly focused team,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. “In December, we look forward to results from Cohort 1 of our ZENITH20 study investigating poziotinib in lung cancer patients with hard-to-treat mutations. We recently submitted our BLA for ROLONTIS to the FDA, a key milestone, as we continue to execute on our strategic priorities.”
For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- American Express (AXP) down despite beating Q1 estimates on top and bottom lines
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!